Enlivex Announces Favorable 12-Month Topline Data from Phase IIa Knee Osteoarthritis Trial

Enlivex reported favorable 12-month topline results from the Phase IIa portion of its multi-country trial of Allocetra for moderate to severe knee osteoarthritis. At 12 months, 79.2% of patients receiving Allocetra were responders, compared with 47.6% on placebo (p=0.027), consistent with response rates at three and six months. The company said it is advancing Allocetra as part of its clinical-stage pipeline for inflammatory conditions.